Replimune is resubmitting its twice-rejected melanoma drug after FDA leadership exodus
Cris Tolomia
·
2026-05-29
·
via Quartz
The FDA rejected vusolimogene oderparepvec twice under former Commissioner Marty Makary, who stepped down ear…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。